Switch theme
Sign up to access all valuation multiples
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
n/a
Last FY Revenue $5.9M
Last FY EBITDA $2.2M
$42.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Vytrus Biotech achieved revenue of $5.9M and an EBITDA of $2.2M.
Vytrus Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vytrus Biotech valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $5.9M | XXX | XXX | XXX |
| Gross Profit | XXX | $6.5M | XXX | XXX | XXX |
| Gross Margin | XXX | 109% | XXX | XXX | XXX |
| EBITDA | XXX | $2.2M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 36% | XXX | XXX | XXX |
| EBIT | XXX | $1.2M | XXX | XXX | XXX |
| EBIT Margin | XXX | 20% | XXX | XXX | XXX |
| Net Profit | XXX | $1.2M | XXX | XXX | XXX |
| Net Margin | XXX | 20% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Vytrus Biotech's stock price is EUR 5 (or $6).
Vytrus Biotech has current market cap of EUR 36.1M (or $42.5M), and EV of EUR 36.1M (or $42.5M).
See Vytrus Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $42.5M | $42.5M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Vytrus Biotech has market cap of $42.5M and EV of $42.5M.
Vytrus Biotech's trades at 7.1x EV/Revenue multiple, and 19.7x EV/EBITDA.
Equity research analysts estimate Vytrus Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vytrus Biotech's P/E ratio is not available.
See valuation multiples for Vytrus Biotech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $42.5M | XXX | $42.5M | XXX | XXX | XXX |
| EV (current) | $42.5M | XXX | $42.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 7.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 19.7x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 35.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 35.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 56.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVytrus Biotech's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Vytrus Biotech's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Vytrus Biotech's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Vytrus Biotech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | 30% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 36% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | 59% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 89% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vytrus Biotech acquired XXX companies to date.
Last acquisition by Vytrus Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Vytrus Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| Where is Vytrus Biotech headquartered? | Vytrus Biotech is headquartered in Spain. |
| Is Vytrus Biotech publicy listed? | Yes, Vytrus Biotech is a public company listed on MAD. |
| What is the stock symbol of Vytrus Biotech? | Vytrus Biotech trades under VYT ticker. |
| When did Vytrus Biotech go public? | Vytrus Biotech went public in 2022. |
| Who are competitors of Vytrus Biotech? | Similar companies to Vytrus Biotech include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Vytrus Biotech? | Vytrus Biotech's current market cap is $42.5M |
| Is Vytrus Biotech profitable? | Yes, Vytrus Biotech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
